AU2016250200B2 - Chimeric protein - Google Patents

Chimeric protein Download PDF

Info

Publication number
AU2016250200B2
AU2016250200B2 AU2016250200A AU2016250200A AU2016250200B2 AU 2016250200 B2 AU2016250200 B2 AU 2016250200B2 AU 2016250200 A AU2016250200 A AU 2016250200A AU 2016250200 A AU2016250200 A AU 2016250200A AU 2016250200 B2 AU2016250200 B2 AU 2016250200B2
Authority
AU
Australia
Prior art keywords
ser
ile
cells
cell
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016250200A
Other languages
English (en)
Other versions
AU2016250200A1 (en
Inventor
Brian PHILIP
Martin PULÉ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of AU2016250200A1 publication Critical patent/AU2016250200A1/en
Assigned to UCL BUSINESS LTD reassignment UCL BUSINESS LTD Amend patent request/document other than specification (104) Assignors: UCL BUSINESS PLC
Application granted granted Critical
Publication of AU2016250200B2 publication Critical patent/AU2016250200B2/en
Assigned to Autolus Limited reassignment Autolus Limited Request for Assignment Assignors: UCL BUSINESS LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016250200A 2015-04-13 2016-04-12 Chimeric protein Ceased AU2016250200B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506223.5A GB201506223D0 (en) 2015-04-13 2015-04-13 Chimeric protein
GB1506223.5 2015-04-13
PCT/GB2016/051019 WO2016166521A1 (en) 2015-04-13 2016-04-12 Chimeric protein

Publications (2)

Publication Number Publication Date
AU2016250200A1 AU2016250200A1 (en) 2017-10-26
AU2016250200B2 true AU2016250200B2 (en) 2020-08-13

Family

ID=53333686

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016250200A Ceased AU2016250200B2 (en) 2015-04-13 2016-04-12 Chimeric protein

Country Status (10)

Country Link
US (1) US10869911B2 (https=)
EP (1) EP3283526B1 (https=)
JP (1) JP6704411B2 (https=)
CN (1) CN107531804A (https=)
AU (1) AU2016250200B2 (https=)
CA (1) CA2981846A1 (https=)
ES (1) ES2749903T3 (https=)
GB (1) GB201506223D0 (https=)
HK (1) HK1243107B (https=)
WO (1) WO2016166521A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
AU2019403393B2 (en) * 2018-12-20 2026-04-16 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
WO2021102250A1 (en) * 2019-11-21 2021-05-27 Luppino Francesco Growth factor restoration
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2021198163A1 (en) * 2020-04-01 2021-10-07 Medigene Immunotherapies Gmbh Cd3-fusion protein and uses thereof
EP4199947A4 (en) 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
JP2024527882A (ja) * 2021-07-21 2024-07-26 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 新規のキメラ抗原受容体及びそれを発現する免疫細胞
AU2023400596A1 (en) * 2022-11-29 2025-06-19 Malcorp Biodiscoveries Limited Novel cd20 protein
CA3278900A1 (en) 2023-03-31 2024-10-03 AbelZeta Inc. BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015152417A1 (ja) * 2014-03-31 2015-10-08 株式会社オーダーメードメディカルリサーチ 目的抗原に対する抗体の作製方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914650D0 (en) * 1999-06-24 1999-08-25 Angyogene Pharmaceuticals Ltd Chimeric proteins mediating targeted apoptosis
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
DK2496698T3 (en) * 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
ES2649991T3 (es) 2012-11-19 2018-01-16 Baliopharm Ag Anticuerpo biespecífico recombinante que se une a CD20 y CD95

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015152417A1 (ja) * 2014-03-31 2015-10-08 株式会社オーダーメードメディカルリサーチ 目的抗原に対する抗体の作製方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANG S, et al., 'Novel CD20 monoclonal antibodies for lymphoma therapy,' Journal of Hematology & Oncology, (2012), vol 5:64, pp 1-9. *

Also Published As

Publication number Publication date
CN107531804A (zh) 2018-01-02
ES2749903T3 (es) 2020-03-24
GB201506223D0 (en) 2015-05-27
HK1243107B (en) 2020-05-08
JP6704411B2 (ja) 2020-06-03
JP2018512154A (ja) 2018-05-17
EP3283526A1 (en) 2018-02-21
CA2981846A1 (en) 2016-10-20
US10869911B2 (en) 2020-12-22
US20180169189A1 (en) 2018-06-21
WO2016166521A1 (en) 2016-10-20
AU2016250200A1 (en) 2017-10-26
EP3283526B1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
AU2016250200B2 (en) Chimeric protein
US11103532B2 (en) Chimeric protein
US20230183311A1 (en) Polypeptide useful in adoptive cell therapy
US9650428B2 (en) Methods and compositions for treating cancer
HK1243107A1 (en) Chimeric protein
JP2021522790A (ja) ホスホリパーゼａ２受容体キメラ自己受容体ｔ細胞の組成物および方法
US20250144137A1 (en) Nucleic acid constructs for expressing polypeptides in cells
KR20220007675A (ko) 아세틸콜린 수용체 키메라 자가항체 수용체 세포의 조성물 및 방법
CN117987435A (zh) 氧依赖性嵌合抗原受体表达及其应用
WO2024261480A1 (en) Constitutive cytokine receptors
HK1236005B (en) Chimeric protein
HK1236005A1 (en) Chimeric protein

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UCL BUSINESS LTD

Free format text: FORMER NAME(S): UCL BUSINESS PLC

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: AUTOLUS LIMITED

Free format text: FORMER OWNER(S): UCL BUSINESS LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired